Peptide Lab HQ Research Guide
FOXO4-DRI
A research-focused compound profile covering FOXO4-DRI identity, senescence-model research applications,
FOXO4-p53 pathway context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | FOXO4-DRI |
|---|---|
| Common Research Name | FOXO4 D-Retro-Inverso peptide |
| Common Synonyms | FOXO4-DRI, FOXO4 DRI, FOXO4 D-Retro-Inverso, FOXO4-p53 interaction peptide, Proxofim reference name |
| Compound Type | Synthetic D-retro-inverso research peptide / senescence-model research compound |
| CAS Number | Not universally standardized across supplier references; verify against supplier COA and batch documentation. |
| Amino Acid Length | Commonly referenced as a long D-retro-inverso peptide; sequence length and salt form should be verified against supplier COA. |
| Sequence | FOXO4-DRI sequence references may vary by supplier, construct, TAT/cell-penetrating domain inclusion, and salt form. Verify the exact sequence against the COA. |
| Molecular Formula | Commonly listed as C228H388N86O64 for FOXO4-DRI; verify final formula by salt form and supplier COA. |
| Molecular Weight | Commonly listed near 5358 Da for FOXO4-DRI; verify exact molecular weight by sequence, salt form, and supplier COA. |
| Research Category | Senescence research / FOXO4-p53 pathway research / cellular-aging model research |
| Research Context | FOXO4-DRI is commonly discussed in controlled research models involving senescent-cell viability, FOXO4-p53 interaction disruption, p53 nuclear exclusion, caspase-associated apoptosis markers, SASP-associated markers, tissue-homeostasis models, and cellular-aging pathway observations. |
| Appearance | Typically supplied as a lyophilized powder; appearance should be verified against supplier COA. |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
FOXO4-DRI is commonly discussed in controlled research models involving cellular senescence,
FOXO4-p53 interaction biology, senescent-cell apoptosis markers, tissue-homeostasis observations,
aging-model research, and pathway-specific senolytic screening.
FOXO4-p53 Pathway Research
Used in research discussions involving disruption of FOXO4 and p53 interaction patterns,
p53 localization, and senescent-cell survival signaling.
Senescent-Cell Research
Commonly discussed in senescence models involving p16, p21, SA-β-gal, DNA damage response,
SASP-associated markers, and apoptosis-resistance observations.
Apoptosis-Marker Research
Research discussions commonly include p53 pathway activity, caspase-3/7 markers,
BAX/BCL-2 balance, nuclear exclusion, and cell-intrinsic apoptosis endpoints.
Aging-Model Research
Used in aging-model discussions involving senescent-cell burden, tissue-homeostasis markers,
inflammatory signaling, and age-associated cellular dysfunction.
Fibroblast / Endothelial Models
FOXO4-DRI has been discussed in senescent fibroblast, endothelial-cell, and tissue-specific
cellular-aging models where senescence and apoptosis markers are tracked.
Senolytic Screening
Commonly discussed as a tool compound for comparing senolytic activity, selectivity,
pathway targeting, and senescent versus non-senescent cell-response patterns.
Research Scope
These applications are provided for educational and research-reference purposes only.
Outcomes may vary based on compound form, purity, sequence, salt form, model type,
concentration, route, exposure duration, endpoint selection, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 10 mg FOXO4-DRI |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 5 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 5 mg/mL, 1 unit equals 0.05 mg / 50 mcg FOXO4-DRI. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light, unless supplier documentation specifies otherwise. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration, peptide format, and supplier formulation. Do not shake!
- Because FOXO4-DRI references may vary by sequence, salt form, and supplier format, verify solubility and handling notes against the COA, batch record, or formula record when available.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light, unless supplier documentation specifies otherwise.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | FOXO4-DRI, FOXO4 D-Retro-Inverso peptide | FOXO4-DRI is commonly discussed as a synthetic D-retro-inverso research peptide designed around FOXO4-p53 interaction biology and senescent-cell viability research. |
| FOXO4-p53 Interaction Research | FOXO4-p53 disruption context | Published research discusses FOXO4-DRI in relation to disrupting FOXO4-p53 binding, p53 localization changes, and senescent-cell apoptosis marker observations. |
| Senescent-Cell Apoptosis Context | Model-dependent senolytic research context | FOXO4-DRI is commonly discussed in senescence models involving selective reduction of senescent-cell viability, caspase-associated apoptosis markers, and non-senescent cell comparison groups. |
| Cellular Aging Research | Senescence-associated tissue-homeostasis context | Research discussions commonly include aging-model endpoints, tissue-homeostasis observations, SASP-associated markers, cellular stress markers, and inflammatory-marker documentation. |
| Fibroblast / Endothelial Model Context | Cell-type-specific senescence research | FOXO4-DRI has appeared in research discussions involving senescent fibroblasts, endothelial cells, Leydig cells, cancer-cell senescence models, and tissue-specific senescence observations. |
| Peptide Design Context | D-retro-inverso / protease-resistance design | D-retro-inverso peptide design is commonly used to preserve binding-interface behavior while improving resistance to proteolytic degradation compared with ordinary L-peptide formats. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references may describe FOXO4-DRI in microgram-to-milligram examples depending on preparation format, model type, and supplier concentration. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, preclinical references, public protocol-style references, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 10 mg | 2.0 mL | 5 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 5 mg/mL | U-100 Unit Reference | Approx. References per 10 mg Vial |
|---|---|---|---|
| 25 mcg | 0.005 mL | 0.5 units | 400 |
| 50 mcg | 0.01 mL | 1 unit | 200 |
| 0.1 mg / 100 mcg | 0.02 mL | 2 units | 100 |
| 0.25 mg / 250 mcg | 0.05 mL | 5 units | 40 |
| 0.5 mg / 500 mcg | 0.10 mL | 10 units | 20 |
| 1 mg / 1000 mcg | 0.20 mL | 20 units | 10 |
| 2 mg / 2000 mcg | 0.40 mL | 40 units | 5 |
| 5 mg / 5000 mcg | 1.00 mL | 100 units | 2 |
| 10 mg / 10000 mcg | 2.00 mL | 200 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 25 mcg reference amount | 0.5 units / 0.005 mL |
| Standard Microgram Reference | Calculation reference only | 50 mcg reference amount | 1 unit / 0.01 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.1 mg reference amount | 2 units / 0.02 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 5 units / 0.05 mL |
| Upper Conversion Example | Calculation reference only | 0.5 mg reference amount | 10 units / 0.10 mL |
| High Conversion Example | Calculation reference only | 1 mg reference amount | 20 units / 0.20 mL |
| 2 mg Preparation Reference | Preparation-level calculation reference | 2 mg reference amount | 40 units / 0.40 mL |
| Half-Vial Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 100 units / 1.00 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 200 units / 2.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Senescence Marker Window | 24–72 hours | May be used for senescent-cell viability markers, p53 localization markers, caspase-associated markers, SA-β-gal markers, SASP-related markers, or pathway-response documentation depending on the model. |
| Acute Pathway Observation Window | Single session to several days | Used for short-term FOXO4-p53 pathway observation, apoptosis-marker comparison, cellular-stress marker tracking, or early senolytic-response documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for controlled observation involving senescent-cell burden, viability markers, apoptosis markers, inflammatory-marker context, or tissue-specific cell-model endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks or longer | Used when longer documentation is needed for senescence-marker trends, tissue-homeostasis observations, inflammatory-marker comparison, or delayed follow-up marker tracking. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, senescent-cell marker rebound, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. FOXO4-DRI, also referenced as FOXO4 D-Retro-Inverso peptide, is commonly discussed in senescence-model, FOXO4-p53 interaction, p53 localization, caspase-associated apoptosis marker, senescent-cell viability, SASP-associated marker, aging-model, tissue-homeostasis, and senolytic screening research contexts. This reference uses a 10 mg vial reconstituted with 2.0 mL bacteriostatic water, creating a 5 mg/mL concentration. Sequence, molecular weight, salt form, solubility, and storage conditions should be verified against the supplier COA, batch record, or formula record when available. Published study references, preclinical research references, public protocol-style references, and wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
FOXO4-DRI is commonly discussed in research involving FOXO4-p53 interaction biology,
senescent-cell viability, p53 localization, caspase-associated apoptosis markers,
and senescence-associated tissue-homeostasis observations.
Study Limitations
Findings should be interpreted according to compound identity, sequence, salt form,
purity, model type, concentration, exposure duration, endpoint selection, and
senescence-induction method.
Safety Considerations
Research discussion should account for identity verification, sterility documentation,
endotoxin risk, supplier qualification, batch records, solubility confirmation,
and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent
any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.